XML 29 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows
$ in Thousands
 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Cash flows from operating activities:      
Net income (loss) $ 18,016 $ (62,086)  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization 995 937  
Inventory obsolescence 1,056 1,361  
Stock-based compensation expense 61,273 44,074  
Payment of Pharmakon PIK Interest (9,153) 0  
Non-cash interest expense on royalty financing obligations 39,839 42,469  
Non-cash interest expense on secured term loan and amortization of debt issuance costs 1,387 11,102  
Amortization of discount on investments, net (3,240) (8,713)  
Loss on extinguishment of debt 6,911 0  
Gain on sale of non-financial asset (550) 0  
Changes in operating assets and liabilities:      
Increase in receivables (21,312) (15,402)  
Increase in inventory (1,124) (2,001)  
(Increase) decrease in prepaid expenses and other assets (5,890) 1,385  
Decrease in royalty financing obligations (55,240) (54,308)  
Increase (decrease) in accounts payable and accrued expenses 22,441 (5,625)  
Net cash provided by (used in) operating activities 55,409 (46,807)  
Cash flows from investing activities:      
Acquisitions of property and equipment (1,666) (449)  
Purchases of investments (136,737) (227,235)  
Sales and maturities of investments 207,647 262,480  
Sale of non-financial asset 550 0  
Net cash provided by investing activities 69,794 34,796  
Cash flows from financing activities:      
Net proceeds from common stock issued under stock-based compensation plans 8,458 4,030  
Common stock issued to directors in lieu of cash retainer 36 29  
Repayment of Pharmakon term loan principal (115,847) 0  
Prepayment premium and fees on Pharmakon term loan (3,802) 0  
Principal payments on royalty financing obligations (16,406) 0  
Withholding taxes paid on stock-based awards (2,845) (4,451)  
Principal payments on finance lease liabilities (1,565) (1,348)  
Net cash used in financing activities (131,971) (1,740)  
Effect of exchange rates on cash, cash equivalents and restricted cash 1,342 368  
Net decrease in cash, and cash equivalents, and restricted cash (5,426) (13,383)  
Less: cash and cash equivalents classified within current assets held for sale (14,840) 0  
Net decrease in cash, and cash equivalents, and restricted cash (20,266) (13,383)  
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation     $ 112,447
Cash, cash equivalents and restricted cash at end of period 86,057 99,064  
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]      
Cash and cash equivalents 84,078 96,841  
Restricted cash 579 813  
Restricted cash in other assets 1,400 1,410  
Total cash, cash equivalents and restricted cash 86,057 99,064  
Supplemental Cash Flow Information [Abstract]      
Cash paid for interest 22,789 20,242  
Cash paid for taxes 2,220 1,225  
Taxes withheld on stock-based awards included in accrued expenses $ 151 $ 245